MACK - Merrimack Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.5200
+0.2800 (+6.60%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.2400
Open4.2600
Bid3.9000 x 1000
Ask0.0000 x 3000
Day's Range4.1500 - 4.5900
52 Week Range2.9111 - 6.1900
Volume233,511
Avg. Volume47,509
Market Cap60M
Beta (5Y Monthly)2.11
PE Ratio (TTM)N/A
EPS (TTM)-2.2130
Earnings DateMar 4, 2020 - Mar 9, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2019-12-13
1y Target Est4.00
  • Business Wire

    Merrimack Pharmaceuticals Adopts Section 382 Net Operating Loss Rights Plan

    Merrimack Pharmaceuticals, Inc. (MACK) (the “Company” or “Merrimack”), announced today that its Board of Directors (the “Board”) has adopted a Section 382 net operating loss rights plan (the “Plan”) and declared a dividend distribution of one Preferred Share Purchase Right on each outstanding share of Company common stock. The Plan is designed to protect the Company’s ability to use its valuable net operating loss (“NOL”) carryforwards and certain other valuable tax attributes. “Preservation of our NOL carryforwards is a key element of our strategic plan and may be used to offset potential corporate tax payments related to future milestones in order to maximize shareholder value,” said Gary Crocker, CEO of the Company.

  • Business Wire

    Merrimack Receives $5 Million Milestone Payment from Ipsen; Declares $6.7 Million Special Dividend

    Merrimack Pharmaceuticals, Inc. (MACK) today announced that it received a $5 million milestone payment from Ipsen, triggered by Ipsen’s decision to progress the ongoing multi-part clinical trial evaluating ONIVYDE in patients with small-cell lung cancer into the second randomized portion of the trial focused on efficacy assessment. As a result of this milestone payment, Merrimack’s Board of Directors has authorized and declared a special cash dividend of $6.7 million on the Company’s common stock (the “Special Dividend”). The Special Dividend is payable on December 23, 2019 to stockholders of record as of the close of business on December 16, 2019.

  • Proxy fights reach 'frightening' level in life sciences, other industries, top attorney says
    American City Business Journals

    Proxy fights reach 'frightening' level in life sciences, other industries, top attorney says

    Attorney and proxy fight expert Kai Liekefett estimated that upwards of 10 percent of public companies have faced activist investor challenges so far this year.

  • PR Newswire

    JFL Capital Ends Campaign at Merrimack

    Pleased Involvement Catalyzed Much Needed Change at Merrimack and Intends to Continue to Monitor Situation LAKEWAY, Texas , Sept. 24, 2019 /PRNewswire/ -- JFL Capital Management, LLC (together with its ...

  • Should You Buy Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) For This Reason?
    Simply Wall St.

    Should You Buy Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) For This Reason?

    As the US$72m market cap Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) released another year of negative earnings...

  • PR Newswire

    JFL Capital Issues Letter to Fellow Merrimack Stockholders

    Believes Significant Destruction of Value and Lack of Alignment with Stockholders Warrants an Overhaul in the Boardroom Highlights Potential Paths Forward to Unlock Stockholder Value that JFL Capital Nominees ...

  • PR Newswire

    Merrimack Declares $20 Million Special Dividend

    CAMBRIDGE, Mass., July 25, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK) today announced that its Board of Directors has authorized and declared a special cash dividend of $20 million on the Company's common stock. The special dividend is payable on September 5, 2019 to stockholders of record as of the close of business on August 28, 2019. The ex-dividend date for the special dividend will be September 6, 2019, the first trading day following the payment date.

  • Benzinga

    The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 30) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Misonix, ...

  • PR Newswire

    Merrimack Pharmaceuticals Announces Completion of Strategic Review, Preservation of Ipsen Milestones and Special Cash Dividend

    CAMBRIDGE, Mass., May 30, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK) today announced the completion of its review of strategic alternatives, following which the Company's Board of Directors is implementing a series of measures designed to extend Merrimack's cash runway into 2027 and preserve its ability to capture the potential remaining ONIVYDE-related milestones resulting from its 2017 asset sale to Ipsen S.A. The Company also announced plans to issue a special cash dividend. The core driver throughout the Company's strategic review process was to optimize value for shareholders, including through the preservation of potential milestone payments that Merrimack is eligible to receive.

  • PR Newswire

    Merrimack Reports First Quarter 2019 Financial Results

    CAMBRIDGE, Mass. , May 10, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), an oncology company focused on biomarker-defined cancers, today announced its first quarter 2019 financial ...

  • Moody's

    COMM 2014-UBS2 Mortgage Trust -- Moody's affirms ten classes of COMM 2014-UBS2

    The ratings on eight P&I classes were affirmed because the transaction's key metrics, including Moody's loan-to-value (LTV) ratio, Moody's stressed debt service coverage ratio (DSCR) and the transaction's Herfindahl Index (Herf), are within acceptable ranges. The rating on the IO class was affirmed based on the credit quality of the referenced classes. The rating on Cl. PEZ was affirmed due to the credit quality of the referenced exchangeable classes.

  • GlobeNewswire

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK

    Pomerantz LLP is investigating claims on behalf of investors of Merrimack Pharmaceuticals, Inc. (“Merrimack” or the “Company”) (NASDAQ: MACK).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. On April 4, 2019, Merrimack announced the discontinuation of work on its sole drug candidate in clinical trials, MM-310, citing safety issues.  Despite amending the protocol for its Phase 1 study after observing and disclosing signs of peripheral neuropathy in clinical trial participants beginning in November, Merrimack reported that subjects taking MM-310 continued to experience weakness, numbness and extremity pain associated with peripheral neuropathy.  On this news, Merrimack’s stock price fell $1.18 per share, or 16.41%, to close at $6.01 per share on April 5, 2019.

  • ACCESSWIRE

    Merrimack Pharmaceuticals, Inc. (MACK) - Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation

    NEW YORK, NY / ACCESSWIRE / April 8, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Merrimack Pharmaceuticals, Inc. (''Merrimack'' or the ''Company'') ...

  • The Merrimack Pharmaceuticals (NASDAQ:MACK) Share Price Is Down 92% So Some Shareholders Are Rather Upset
    Simply Wall St.

    The Merrimack Pharmaceuticals (NASDAQ:MACK) Share Price Is Down 92% So Some Shareholders Are Rather Upset

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! It is a pleasure to report that the Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is up 58% in the last quarter. But...

  • Benzinga

    The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 4) AEterna Zentaris Inc. (NASDAQ: AEZS ) GALAPAGOS NV/S ...

  • PR Newswire

    Merrimack Discontinues Development of MM-310

    CAMBRIDGE, Mass., April 4, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK), an oncology company focused on biomarker-defined cancers, today announced the Company is discontinuing development of MM-310, its antibody-directed nanotherapeutic for the treatment of solid tumors. Based on emerging data since the recent amendment of the clinical protocol, the Company has concluded that the study would not be able to reach an optimal therapeutic index for MM-310.